Reports Q3 revenue $3.28B, consensus $3.26B. “Labcorp (LH) achieved strong performance in Diagnostics and Biopharma Laboratories, including robust organic growth in the third quarter,” said Adam Schechter, chairman and CEO of Labcorp. “Our results demonstrate momentum in our core businesses as we introduced new tests, and extended our leadership position in specialty testing. We announced or completed several transactions with health systems and regional/local laboratories, which aligns with our acquisition strategy. We are on track to finish 2024 with strong growth as we focus on science, technology, and innovation and bring new tests and services to our customers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Notable companies reporting before tomorrow’s open
- Activist Corvex acquires stake in Fortrea Holdings, Bloomberg reports
- Laboratory Corporation Of America (LH) Q3 Earnings Cheat Sheet
- Labcorp named exclusive distributor of First To Know Syphilis Test
- Labcorp price target lowered to $234 from $249 at Barclays